培美曲塞联合替吉奥胶囊治疗晚期老年非小细胞肺癌的临床研究

Clinical Research of Pemetrexed Combined with Tegafur Gimeracil Oteracil Potassium Capsule For Elderly Patients with Advanced Non-small Cell Lung Cancer

目的:探讨培美曲塞联合替吉奥方案治疗晚期老年非小细胞肺癌的临床疗效。方法:将50例老年晚期非小细胞肺癌患者按随机数字表法分为治疗组和对照组。治疗组25例,给予培美曲赛+替吉奥方案化疗,对照组25例,给予最佳支持治疗(best supportive care,BSC)。观察两组治疗结束后3个月的近期疗效、1年和2年生存率及不良反应。结果:治疗结束后3个月,治疗组的客观有效率为48.0%,对照组为8.0%,两组比较差异具有统计学意义(P=0.002)。治疗组和对照组的1、2年生存率分别为41.7%、4.2%和29.2%、0,两组比较差异有显著统计学意义(P<0.001)。治疗组的毒副反应主要为骨髓抑制(白细胞下降、贫血、血小板下降)、肝肾功损伤,对照组未出现明显毒副反应。结论:培美曲塞联合替吉奥方案治疗晚期老年非小细胞肺癌可提高近期疗效及1、2年生存率,可作为老年晚期非小细胞肺癌的一种安全、有效的治疗方法。

Objective：To investigate the clinical effect of pemetrexed combined with tegafur gimeracil oteracil potassium capsule for elderly patients with advanced non-small cell lung cancer.Method： 50 elderly patients with advanced non-small cell lung cancer were randomly divided into treatment group and control group. In the treatment group, 25 patients received pemetrexed ＋ tegafur gimeracil oteracil potassium capsule chemotherapy. In the control group, 25 patients received best supportive care （BSC）. Term efficacy, long-term survival and adverse reactions was compared between the two groups.Result： Two months after the end of treatment, the objective response rate of the treatment group and control group was 48.0% and 8.0%, respectively, there were statistically significant differences between the two groups （P=0.002）. The 1, 2-year survival rates of the treatment group and the control group and was 41.7%, 4.2%, and 29.2%, 0, there was significant difference beween the two groups （P〈0.001）. The main toxicities in the treatment group was myelosuppression （leukopenia, anemia, thrombocytopenia）, liver and kidney function damage, there was no obvious toxicity in the control group.Conclusion：Pemetrexed combined with tegafur gimeracil oteracil potassium capsule can improve the efficacy and 1,2-year survival rate, it can be used as a safe and effective method for elderly patients with advanced non-small cell lung cancer.